Compare CRDL & NAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDL | NAZ |
|---|---|---|
| Founded | 2017 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 146.0M |
| IPO Year | N/A | N/A |
| Metric | CRDL | NAZ |
|---|---|---|
| Price | $0.99 | $11.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 409.9K | 18.3K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $9.22 |
| 52 Week High | $1.59 | $11.37 |
| Indicator | CRDL | NAZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 47.77 |
| Support Level | $0.94 | $11.86 |
| Resistance Level | $1.03 | $11.98 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 26.53 | 59.98 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.